STAAR® Surgical Company, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or “ICL.” A lens used to replace the natural lens after cataract surgery is called an intraocular lens or “IOL.” Over 500,000 Visian ICLs have been implanted to date. STAAR has approximately 300 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, conducts operations in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.
STAAR SURGICAL OPERATIONS
STAAR® has significant operations globally. STAAR sells its products in over 60 countries, with direct distribution in North America, Japan, and Spain, with independent distribution in the remainder of the world.
STAAR maintains manufacturing and administrative facilities in the United States and an administrative facility in Japan. While STAAR has initiated a project to consolidate all of its manufacturing to its Monrovia, California facility, its current global operations are as follows:
STAAR operates its global administrative headquarters and a manufacturing facility in Monrovia, California. The Monrovia manufacturing facility principally makes Collamer® IOLs, silicone IOLs, silicone preloaded IOLs, Visian ICL® products and injector systems for IOLs and ICLs. STAAR also currently manufactures the raw material for Collamer lenses (both IOLs and ICLs) and the AquaFlow™ Device (for the treatment of glaucoma) in a facility in Aliso Viejo, California.
STAAR operates an administrative, manufacturing and distribution facility in Nidau, Switzerland under its wholly owned subsidiary, STAAR Surgical AG. The Nidau manufacturing facility makes Visian ICL® products and also manufactures the AquaFlow Device. After consolidating manufacturing in Monrovia, California, STAAR plans to continue to maintain an administrative and distribution facility in Switzerland.
STAAR operates administrative and distribution facilities in Japan under its wholly owned subsidiary, STAAR Japan Inc. STAAR Japan’s administrative facility is located in Shin-Urayasu and its distribution facility is located in Ichikawa City. Manufacturing has been consolidated to Monrovia, Californi
STAAR SURGICAL HISTORY
STAAR® developed, patented, and licensed the first foldable intraocular lens, or IOL, for cataract surgery. Made of pliable material, the foldable IOL permitted surgeons for the first time to replace a cataract patient’s natural lens with minimally invasive surgery. The foldable IOL became the standard of care for cataract surgery throughout the world. STAAR introduced its first versions of the lens, made of silicone, in 1991.
In 1996 STAAR began selling the Visian ICL® outside the U.S. Made of STAAR’s proprietary biocompatible Collamer® lens material, the ICL is implanted behind the iris and in front of the patient’s natural lens to treat refractive errors such as myopia, hyperopia, and astigmatism. Lenses of this type are generically called “phakic IOLs” or “phakic implants” because they work along with the patient’s natural lens rather than replacing it. The ICL received CE Mark in 1997, permitting sale in countries that require the European Union CE Mark, and it received FDA approval for the treatment of myopia in the U.S. in December 2005. The Visian ICL now makes up approximately 62% of our business. We sell the Visian ICL in more than 60 countries, and it has been implanted in more than 500,000 eyes worldwide.
Other milestones in STAAR’s history include the following:
- In 1991, STAAR introduced the first versions of the foldable, silicone IOL.
- In 1996, STAAR began selling the Visian ICL outside the United States.
- In 1998, STAAR introduced the Toric IOL, the first implantable lens approved for the treatment of preexisting astigmatism.
- In 2000, STAAR introduced an IOL made of the Collamer material, offering cataract patients and their surgeons the same clarity, refractive qualities and biocompatibility featured by the Visian ICL.
- In 2001, STAAR commenced commercial sales of its Visian Toric ICL® or TICL, which corrects both astigmatism and myopia, outside the U.S. In 2002, the TICL received CE Marking, allowing commercial sales in countries that require the European Union CE Mark. Today we market the TICL worldwide, except for the U.S.
- In late 2003, STAAR Japan introduced the first preloaded IOL lens injector system in international markets. The Preloaded Injector offers surgeons improved convenience and reliability. The Preloaded Injector is not yet available in the U.S.
- On December 22, 2005, the FDA approved the Visian ICL for the treatment of myopia, making it the first, and to date only, small incision phakic IOL commercially available in the United States
- Beginning in 2007, STAAR introduced its first aspheric IOLs made of silicone and Collamer.
- On December 29, 2007 , STAAR acquired the 50% remaining interests in STAAR Japan, making this former joint venture a wholly owned subsidiary of STAAR.
- On February 2, 2010, the Japanese Ministry of Health, Labor and Welfare approved the Visian ICL, making it the first phakic IOL approved for sale in Japan.
- In September, 2010, STAAR launched the expanded range Visian ICL – version V4b – in Europe and other territories that recognize the European Union CE Mark. The expanded range allows for the treatment of virtually any myopic or hyperopic refractive error.
- In April, 2011, the Visian ICL® with CentraFLOW™ – version V4c – technology received the CE Mark Approval in Europe and other territories that recognize the CE Mark. CentraFLOW technology uses a proprietary port in the center of the ICL optic. The port has a size determined to optimize the flow of fluid within the eye without affecting the quality of vision, and eliminates the need for the surgeon to perform a YAG peripheral iridotomy procedure or a surgical irid ectomy. By simplifying the procedure and increasing patient comfort, the Visian ICL with CentraFLOW makes the superior visual outcomes of the Visian ICL available through an experience closer to LASIK.
- In November, 2011, the Japanese Ministry of Health, Labor and Welfare approved the Toric ICL.
- In August, 2012, STAAR announced expansion to a larger facility at the Monrovia headquarters.
- In September, 2012, STAAR announced details of its direct sales model in Spain.
- In April, 2013, STAAR celebrated 350,000 Visian ICL implants.
- In June, 2013, Visian ICL V4C with CentraFlow was approved in Korea and Argentina.
- In August, 2013, Visian ICL V4C with CentraFlow was approved in India.
STAAR Surgical Photos
RecommendsPositive OutlookNo opinion of CEO
- Work/Life Balance
- Culture & Values
- Career Opportunities
- Comp & Benefits
- Senior Management
I have been working at STAAR Surgical part-time (Less than a year)
STAAR provides a professional working environment and provides excellent compensation and benefits.
STAAR is a very high pressure environment. They take their work very seriously.
Getting an Interview
Getting an Interview
- Accepted OfferPositive ExperienceEasy Interview
I applied through a recruiter. The process took 2 days. I interviewed at STAAR Surgical (Los Angeles, CA) in March 2014.
two telephone interviews -one with a recruiter and one with a direct-report. surprised that no one higher up was interested enough to interview me, but after starting work understood why. the company has far greater concerns.
- tell me about yourself, tell me more about yourself. Tell me about the last place you worked and why you left that place. 1 Answer
negotiation was with an agency that claimed since staar is a small company I should not expect it to pay competitive rates.
Let us know if we're missing any workplace or industry recognition –
STAAR Surgical won't put stars in your eyes, but it will help you to see more clearly. The company makes products for minimally invasive ophthalmic surgical procedures. Its primary products are foldable intraocular lenses (IOLs), which replace natural lenses removed in cataract surgery. STAAR also makes Visian-branded implantable lenses (ICLs) for correction of refractive conditions, such as near- and far-sightedness and astigmatism. Other products include the AquaFlow device, an implantable device used to treat glaucoma. STAAR's products are sold in more than ...